The authors declare that they have no competing interests.
DZ: conceived, designed and supervised the study as well as reviewed the manuscript; collected samples and provided clinical data, contributed to data analysis and interpretation and wrote the manuscript. DJ: conceived, designed and supervised the study as well as reviewed the manuscript; collected samples and provided clinical data, contributed to data analysis and interpretation. MA: conceived, designed and supervised the study as well as reviewed the manuscript; collected samples and provided clinical data, contributed to data analysis and interpretation and wrote the manuscript. ZC: performed the lab analysis, contributed to data analysis and interpretation. KJ: collected samples and provided clinical data. AG: edited and reviewed the revised manuscript. AKZ: contributed to data interpretation, wrote the manuscript, edited and reviewed the manuscript. All authors read and approved the final manuscript.
Angiogenesis is an important process involved in the pathogenesis of diffuse parenchymal lung diseases. The aim of the study was to compare the angiogenic profile of patients with sarcoidosis and idiopathic pulmonary fibrosis (IPF) based on analysis of circulating factors.
Serum concentrations of angiopoietin-2 (Ang-2), follistatin, granulocyte-macrophage-colony stimulating factor (GM-CSF), interleukin-8 (IL-8), platelet derived growth factor-BB (PDGF-BB), platelet endothelial cellular adhesion molecule-1 (PECAM-1) and vascular endothelial growth factors (VEGF) were measured in the patients and the healthy subjects.
Serum concentrations of G-CSF, follistatin, PECAM-1 and IL-8 were significantly higher in the IPF patients in comparison with the control group and the sarcoid patients. PDGF-BB concentrations were also significantly higher in serum of IPF patients than in sarcoid patients, but not than in the controls. In contrast, Ang-2 and VEGF concentrations did not differ significantly between the three groups. In the sarcoid patients, irrespective of the disease activity or the radiological stage, serum concentrations of these cytokines were similar to the control group.
These results indicate that differences may exist in angiogenic activity between patients with parenchymal lung diseases. In contrast to sarcoidosis, IPF is characterized by a higher serum concentration of different molecules involved in the angiogenic processes .
Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG Statement on sarcoidosis. Am J Respir Crit Care Med. 1999;160:736–55. CrossRef
Keane MP. The role of chemokines and cytokines in lung fibrosis. Eur Respir Rev. 2008;17:151–6. CrossRef
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Aniopietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;227:55–60. CrossRef
Koczy-Baron E, Kasperska-Zajac A. The role of vascular endothelial growth factor in inflammatory processes. Postepy Hig Med Dosw. 2014;68:57–65. CrossRef
Ziora D, Adamek M, Czuba Z, Jastrzębski D, Zeleznik K, Kasperczyk S, et al. Increased Serum Hepatocyte Growth Factor (HGF) Levels in Patients with Idiopathic Pulmonary Fibrosis (IPF) or Progressive Sarcoidosis. J Mol Biomark Diagn. 2014;5:2–4. CrossRef
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2015;26:319–38. CrossRef
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5–40. CrossRefPubMed
Keane MP, Arenberg DA, Lynch 3rd JP, Whyte RI, Iannettoni MD, Burdick MD, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol. 1997;159:1437–43. PubMed
Antoniou KM, Soufla G, Proklou A, Margaritopoulos G, Choulaki C, Lymbouridou R, et al. Different activity of the biological axis VEGF-Flt-1 (fms-Like Tyrosine Kinase 1) and CXC chemokines between pulmonary sarcoidosis and idiopathic pulmonary fibrosis: A Bronchoalveolar Lavage Study. Clin Dev Immunol. 2009;537929.
Ziora D, Dworniczak S, Niepsuj G, Niepsuj K, Jarosz W, Sielska-Sytek E, et al. Proangiogenic cytokines (bFGF and VEGF) in BALF from two different segments of lungs defined by high resolution computerized tomography (HRCT) in patients with sarcoidosis. Pneumonol Alergol Pol. 2000;68:120–30. PubMed
Ziora D, Dworniczak S, Niepsuj G, Grzanka P, Cieślicki J, Kozielski J, et al. Cytokines TNF-alpha and GM-CSF in BAL from two different segments of lungs defined by high resolution computerized tomography (HRCT) in patients with sarcoidosis. Pneumonol Alergol Pol. 2000;68:336–46. PubMed
Cao B, Guo Z, Zhu Y, Xu W. The potential role of PDGF, IGF-1, TGF-beta expression in idiopathic pulmonary fibrosis. Chin Med J. 2000;113:776–82. PubMed
Margaritopoulos GA, Antoniou KM, Karagiannis K, Vassalou E, Lasithiotaki I, Lambiri I, et al. Investigation of angiogenic axis Anigiopoietin-1 and 2/Tie-2 in fibrotic lung diseases: a bronchoalveolar lavage study. Int J Mol Med. 2010;26:919–23. PubMed
- Circulating concentration of markers of angiogenic activity in patients with sarcoidosis and idiopathic pulmonary fibrosis
Jerzy Kozielski J.
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II